| Document Date: 2015-03-11 17:23:00
Open Document File Size: 2,61 MBShare Result on Facebook
City London / Klinikum Ludwigshafen / / Company Bayer Pharma AG / Novartis Pharma AG / Allergan / Retinal Vein Occlusion Management / Genentech / EyeTube.net / Novartis Pharmaceuticals / Ford / BRVO / Bayer Healthcare Pharmaceuticals / / Continent Asia / Europe / / Country Germany / United States / Australia / Spain / / / Facility National Eye Institute / / IndustryTerm long-term management / overall management / / MedicalCondition ranch retinal vein occlusion / vascular disease / macular edema / arterial hypertension / HORIZONS IN RETINAL VEIN OCCLUSION MANAGEMENT / macular edema secondary / mild disease / entral retinal vein occlusion / ischemia and longer disease duration / retinal vein occlusions / proteinuria / neovascular glaucoma / hypertension / central retinal vein occlusion / disease / RVO-related disease / common retinal vascular disease / diabetes / Systemic diseases / high cholesterol / branch retinal vein occlusion / retinal vein occlusion / / MedicalTreatment retreatment / Laser therapy / laser treatment / Laser treatments / / Organization National Eye Institute / Research for Vision in Barcelona / Macula / European Union / / Person LARS-OLOF HATTENBACH / JORDI MONÉS / MICHAEL LARSEN / Arch Ophthalmol / / Position investigator / consultant / Singer / director / professor of ophthalmology and director of the department / / Product BRAVO / Laser / PRN injections / dexamethasone / Lucentis / / PublishedMedium BRAVO / / Technology tomography / laser / /
SocialTag |
Supplement to March 2015 Ranibizumab: Expanding